Skip to main content
Top
Published in: Gastric Cancer 3/2018

Open Access 01-05-2018 | Original Article

Factors influencing health-related quality of life after gastrectomy for cancer

Authors: Hylke J. F. Brenkman, Juul J. W. Tegels, Jelle P. Ruurda, Misha D. P. Luyer, Ewout A. Kouwenhoven, Werner A. Draaisma, Donald L. van der Peet, Bas P. L. Wijnhoven, Jan H. M. B. Stoot, Richard van Hillegersberg, on behalf of the LOGICA Study Group

Published in: Gastric Cancer | Issue 3/2018

Login to get access

Abstract

Aim

Insight in health-related quality of life (HRQoL) may improve clinical decision making and inform patients about the long-term effects of gastrectomy. This study aimed to evaluate and identify factors associated with HRQoL after gastrectomy.

Methods

This cross-sectional study used prospective databases from seven Dutch centers (2001–2015) including patients who underwent gastrectomy for cancer. Between July 2015 and November 2016, European Organization for Research and Treatment of Cancer HRQoL questionnaires QLQ-C30 and QLQ-STO22 were sent to all surviving patients without recurrence. The QLQ-C30 scores were compared to a Dutch reference population using a one-sample t test. Spearman’s rank test was used to correlate time after surgery to HRQoL, and multivariable linear regression was performed to identify factors associated with HRQoL.

Results

A total of 222 of 274 (81.0%) patients completed the questionnaires. Median follow-up was 29 months (range, 3–171) and 86.9% of patients had a follow-up >1 year. The majority of patients had undergone neoadjuvant treatment (64.4%) and total gastrectomy (52.7%). Minimally invasive gastrectomy (MIG) was performed in 50% of the patients. Compared to the general population, gastrectomy patients scored significantly worse on most functional and symptom scales (p < 0.001) and slightly worse on global HRQoL (78 vs. 74, p = 0.012). Time elapsed since surgery did not correlate with global HRQoL (Spearman’s ρ = 0.06, p = 0.384). Distal gastrectomy, neoadjuvant treatment, and MIG were associated with better HRQoL (p < 0.050).

Conclusion

After gastrectomy, patients encounter functional impairments and symptoms, but experience only a slightly impaired global HRQoL. Distal gastrectomy, the ability to receive neoadjuvant treatment, and MIG may be associated with HRQoL benefits.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
go back to reference Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069–77.CrossRefPubMed Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069–77.CrossRefPubMed
3.
go back to reference Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.CrossRefPubMed Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.CrossRefPubMed
4.
go back to reference Blazeby JM, Conroy T, Bottomley A, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004;40:2260–8.CrossRefPubMed Blazeby JM, Conroy T, Bottomley A, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004;40:2260–8.CrossRefPubMed
6.
go back to reference Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17:3077–9.CrossRefPubMed Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17:3077–9.CrossRefPubMed
7.
go back to reference Edge S, Byrd D, Compton C, et al. AJCC cancer staging manual. New York: Springer; 2010. Edge S, Byrd D, Compton C, et al. AJCC cancer staging manual. New York: Springer; 2010.
8.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed
9.
go back to reference Fayers P, Aaronson N, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual. Brussels: European Organisation for Research and Treatment of Cancer; 2001. Fayers P, Aaronson N, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
10.
go back to reference van de Poll-Franse LV, Mols F, Gundy CM, et al. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer. 2011;47:667–75.CrossRefPubMed van de Poll-Franse LV, Mols F, Gundy CM, et al. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer. 2011;47:667–75.CrossRefPubMed
11.
go back to reference Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.CrossRefPubMed Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.CrossRefPubMed
12.
go back to reference Karanicolas PJ, Graham D, Gonen M, et al. Quality of life after gastrectomy for adenocarcinoma: a prospective cohort study. Ann Surg. 2013;257:1039–46.CrossRefPubMedPubMedCentral Karanicolas PJ, Graham D, Gonen M, et al. Quality of life after gastrectomy for adenocarcinoma: a prospective cohort study. Ann Surg. 2013;257:1039–46.CrossRefPubMedPubMedCentral
13.
go back to reference Lee SS, Chung HY, Kwon OK, et al. Long-term quality of life after distal subtotal and total gastrectomy: symptom- and behavior-oriented consequences. Ann Surg. 2016;263:738–44.CrossRefPubMed Lee SS, Chung HY, Kwon OK, et al. Long-term quality of life after distal subtotal and total gastrectomy: symptom- and behavior-oriented consequences. Ann Surg. 2016;263:738–44.CrossRefPubMed
14.
go back to reference Lee SS, Chung HY, Kwon O, et al. Long-term shifting patterns in quality of life after distal subtotal gastrectomy: preoperative- and healthy-based interpretations. Ann Surg. 2015;261:1131–7.CrossRefPubMed Lee SS, Chung HY, Kwon O, et al. Long-term shifting patterns in quality of life after distal subtotal gastrectomy: preoperative- and healthy-based interpretations. Ann Surg. 2015;261:1131–7.CrossRefPubMed
15.
go back to reference Kim YW, Baik YH, Yun YH, et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg. 2008;248:721–7.CrossRefPubMed Kim YW, Baik YH, Yun YH, et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg. 2008;248:721–7.CrossRefPubMed
16.
go back to reference Avery K, Hughes R, McNair A, et al. Health-related quality of life and survival in the 2 years after surgery for gastric cancer. Eur J Surg Oncol. 2010;36:148–54.CrossRefPubMed Avery K, Hughes R, McNair A, et al. Health-related quality of life and survival in the 2 years after surgery for gastric cancer. Eur J Surg Oncol. 2010;36:148–54.CrossRefPubMed
17.
go back to reference Dikken JL, van Sandick JW, Maurits Swellengrebel HA, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11:329.CrossRefPubMedPubMedCentral Dikken JL, van Sandick JW, Maurits Swellengrebel HA, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11:329.CrossRefPubMedPubMedCentral
18.
go back to reference Akkerman RD, Haverkamp L, van Rossum PS, et al. Long-term quality of life after oesophagectomy with gastric conduit interposition for cancer. Eur J Cancer. 2015;51:1538–45.CrossRefPubMed Akkerman RD, Haverkamp L, van Rossum PS, et al. Long-term quality of life after oesophagectomy with gastric conduit interposition for cancer. Eur J Cancer. 2015;51:1538–45.CrossRefPubMed
19.
go back to reference Arndt V, Merx H, Sturmer T, et al. Age-specific detriments to quality of life among breast cancer patients one year after diagnosis. Eur J Cancer. 2004;40:673–80.CrossRefPubMed Arndt V, Merx H, Sturmer T, et al. Age-specific detriments to quality of life among breast cancer patients one year after diagnosis. Eur J Cancer. 2004;40:673–80.CrossRefPubMed
20.
go back to reference Blome C, Augustin M. Measuring change in quality of life: bias in prospective and retrospective evaluation. Value Health. 2015;18:110–5.CrossRefPubMed Blome C, Augustin M. Measuring change in quality of life: bias in prospective and retrospective evaluation. Value Health. 2015;18:110–5.CrossRefPubMed
21.
go back to reference Kim W, Kim HH, Han SU, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg. 2015;263:28–35.CrossRef Kim W, Kim HH, Han SU, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg. 2015;263:28–35.CrossRef
22.
go back to reference Hu Y, Huang C, Sun Y, et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol. 2016;34:1350–7.CrossRefPubMed Hu Y, Huang C, Sun Y, et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol. 2016;34:1350–7.CrossRefPubMed
23.
go back to reference Katai H, Mizusawa J, Katayama H, et al. Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912. Gastric Cancer. 2017;20:699–708.CrossRefPubMed Katai H, Mizusawa J, Katayama H, et al. Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912. Gastric Cancer. 2017;20:699–708.CrossRefPubMed
24.
go back to reference Brenkman HJ, Ruurda JP, Verhoeven RH, et al. Safety and feasibility of minimally invasive gastrectomy during the early introduction in the Netherlands: short-term oncological outcomes comparable to open gastrectomy. Gastric Cancer 2017 [Epub ahead of print]. Brenkman HJ, Ruurda JP, Verhoeven RH, et al. Safety and feasibility of minimally invasive gastrectomy during the early introduction in the Netherlands: short-term oncological outcomes comparable to open gastrectomy. Gastric Cancer 2017 [Epub ahead of print].
25.
go back to reference Brenkman HJF, Gisbertz SS, Slaman AE, et al. Postoperative Outcomes of Minimally Invasive Gastrectomy Versus Open Gastrectomy During the Early Introduction of Minimally Invasive Gastrectomy in the Netherlands: A Population-based Cohort Study. Ann Surg. 2017;266(5):831–838.CrossRefPubMed Brenkman HJF, Gisbertz SS, Slaman AE, et al. Postoperative Outcomes of Minimally Invasive Gastrectomy Versus Open Gastrectomy During the Early Introduction of Minimally Invasive Gastrectomy in the Netherlands: A Population-based Cohort Study. Ann Surg. 2017;266(5):831–838.CrossRefPubMed
26.
go back to reference Haverkamp L, Brenkman HJ, Seesing MF, et al. Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial). BMC Cancer. 2015;15:556.CrossRefPubMedPubMedCentral Haverkamp L, Brenkman HJ, Seesing MF, et al. Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial). BMC Cancer. 2015;15:556.CrossRefPubMedPubMedCentral
27.
go back to reference Straatman J, van der Wielen N, Cuesta MA, et al. Surgical techniques, open versus minimally invasive gastrectomy after chemotherapy (STOMACH trial): study protocol for a randomized controlled trial. Trials. 2015;16:123–9.CrossRefPubMedPubMedCentral Straatman J, van der Wielen N, Cuesta MA, et al. Surgical techniques, open versus minimally invasive gastrectomy after chemotherapy (STOMACH trial): study protocol for a randomized controlled trial. Trials. 2015;16:123–9.CrossRefPubMedPubMedCentral
28.
go back to reference Hur H, Lee HY, Lee HJ, et al. Efficacy of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer: the protocol of the KLASS-02 multicenter randomized controlled clinical trial. BMC Cancer. 2015;15:355.CrossRefPubMedPubMedCentral Hur H, Lee HY, Lee HJ, et al. Efficacy of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer: the protocol of the KLASS-02 multicenter randomized controlled clinical trial. BMC Cancer. 2015;15:355.CrossRefPubMedPubMedCentral
29.
go back to reference Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.CrossRef
30.
go back to reference Diaz De Liano A, Oteiza Martinez F, Ciga MA, et al. Impact of surgical procedure for gastric cancer on quality of life. Br J Surg. 2003;90:91–4.CrossRefPubMed Diaz De Liano A, Oteiza Martinez F, Ciga MA, et al. Impact of surgical procedure for gastric cancer on quality of life. Br J Surg. 2003;90:91–4.CrossRefPubMed
32.
go back to reference Jack S, West MA, Raw D, et al. The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. Eur J Surg Oncol. 2014;40:1313–20.CrossRefPubMed Jack S, West MA, Raw D, et al. The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. Eur J Surg Oncol. 2014;40:1313–20.CrossRefPubMed
33.
go back to reference Yu W, Park KB, Chung HY, et al. Chronological changes of quality of life in long-term survivors after gastrectomy for gastric cancer. Cancer Res Treat. 2016;48:1030–6.CrossRefPubMedPubMedCentral Yu W, Park KB, Chung HY, et al. Chronological changes of quality of life in long-term survivors after gastrectomy for gastric cancer. Cancer Res Treat. 2016;48:1030–6.CrossRefPubMedPubMedCentral
Metadata
Title
Factors influencing health-related quality of life after gastrectomy for cancer
Authors
Hylke J. F. Brenkman
Juul J. W. Tegels
Jelle P. Ruurda
Misha D. P. Luyer
Ewout A. Kouwenhoven
Werner A. Draaisma
Donald L. van der Peet
Bas P. L. Wijnhoven
Jan H. M. B. Stoot
Richard van Hillegersberg
on behalf of the LOGICA Study Group
Publication date
01-05-2018
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 3/2018
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-017-0771-0

Other articles of this Issue 3/2018

Gastric Cancer 3/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.